Alpha Cognition Appoints Cedric O’Gorman, M.D., MBA as Chief Medical Officer
December 2, 2021
VANCOUVER, B.C., December 2, 2021. Alpha Cognition Inc. (TSX-V: ACOG)(OTCQB: ACOGF)(“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today announced the appointment of Cedric O’Gorman, M.D., as the Company’s Chief Medical Officer. Dr. O’Gorman will lead medical, clinical and regulatory functions in support of the company's clinical-stage products ALPHA-1062 and ALPHA-0602. Dr. O’Gorman will also serve as a member of the executive management team, reporting to the CEO.
Dr. O’Gorman brings to Alpha Cognition more than two decades of life sciences experience in clinical development, medical affairs and medical strategy, almost exclusively in the CNS therapeutic area, and across all stages of drug development. Prior to Alpha Cognition, he served as Senior Vice President, Clinical Development and Medical Affairs at Axsome Therapeutics where he led clinical development programs for therapeutic indications which included major depressive disorder, agitation associated with Alzheimer’s disease, narcolepsy, and migraine. Prior to Axsome, Dr. O’Gorman was Vice President of Medical Affairs at Intra-Cellular Therapies and before that, Dr. O’Gorman was the U.S. Medical Lead for Psychiatry at Genentech/Roche. Prior to Genentech/Roche, Dr. O'Gorman spent 5 years at Pfizer representing medical affairs on several branded neuroscience products for schizophrenia, bipolar disorder, and major depressive disorder.
Michael McFadden, CEO of the Company commented: “As a board-certified psychiatrist, Dr. O’Gorman’s addition to the management team provides critical support for the advancement of our clinical programs. His clinical vision and proven leadership, including his extensive CNS medical and research experience, further strengthens our clinical development efforts and support the progress of our product pipeline.”
Dr. O’Gorman additionally commented: "I am excited to be joining Alpha Cognition and look forward to working with the outstanding leadership team to progress the company's multiple programs toward later-stage clinical development, with the goal of getting safe and effective therapies to patients in medical need."
Dr. O'Gorman received his medical degree from the National University of Ireland in Galway, trained at the Institute of Psychiatry in London, England, and earned his Master of Business Administration from the New York University Stern School of Business.
About Alpha Cognition Inc.
Alpha Cognition Inc. is a clinical stage, biopharmaceutical company dedicated to developing treatments for under-served neurodegenerative diseases, such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis (ALS).
ALPHA-1062, is a patented new chemical entity that has demonstrated safety and improved tolerability in human clinical trials. It is being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, with minimal gastrointestinal side effects and novel routes of administration. ALPHA-1062's active metabolites are differentiated from donepezil and rivastigmine in that they may sensitize neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer's dementia and in a nasal spray formulation to treat traumatic brain injury.
ALPHA-0602 (Progranulin) is expressed in several cell types in the central nervous system and in peripheral tissues, regulates cell survival and certain inflammatory processes, and plays a major role in regulating lysosomal function and microglial responses to disease. Its use for the treatment of neurodegenerative diseases has been patented by the Company and granted an Orphan Drug Designation.
For further information:
Neither TSX Venture Exchange (the “TSX-V”), OTC Markets Group, nor the TSX-V’s Regulation Services Provider (as that term is defined in policies of the TSX-V) accepts responsibility for the adequacy or accuracy of this release.
This news release is not, and under no circumstances is to be construed as, an advertisement or a public offering of securities. No securities commission or similar authority in Canada or in any other jurisdiction has reviewed or in any way passed upon this news release or the merits of the securities described herein and any representation to the contrary is an offence.
This news release includes forward-looking statements within the meaning of applicable securities laws. Except for statements of historical fact, any information contained in this news release may be a forward‐looking statement that reflects the Company’s current views about future events and are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Forward‐looking statements can be identified by the words “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “target,” “seek,” “contemplate,” “continue” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward‐looking statements in this news release include statements regarding the Company’s business strategy, market size, potential growth opportunities, capital requirements, clinical development activities, the timing and results of clinical trials, regulatory submissions, potential regulatory approval and commercialization of the technology. Although the Company believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. The Company cannot assure that the actual results will be consistent with these forward-looking statements as a result of known and unknown risks, uncertainties, assumptions and other factors. These risks, uncertainties, assumptions and other factors include those associated with clinical studies and manufacturing, as well as development and commercialization of the Company’s products; the need for additional financing to maintain operations; risks posed by the economic and political environments in which the Company operates and intends to operate; market instability due to the COVID-19 pandemic; the potential for losses arising from the expansion of operations into new markets; increased competition; assumptions regarding market trends and the expected demand and desires for the Company’s products and proposed products; reliance on industry manufacturers, suppliers and key personnel; the failure to adequately protect intellectual property; a failure to adequately manage future growth; adverse market conditions; and failure to satisfy ongoing regulatory requirements or obtain regulatory approvals. These forward‐looking statements speak only as of the date of this news release and, other than as required by applicable securities laws, the Company undertakes no obligation to revise or update any forward‐looking statements, even if new information becomes available in the future.
This news release may also contain estimates and other statistical, market and industry data from independent parties or made by the Company relating to our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. We cannot guarantee the accuracy and completeness of information from third party sources.